Literature DB >> 29566794

Tau Kinetics in Neurons and the Human Central Nervous System.

Chihiro Sato1, Nicolas R Barthélemy2, Kwasi G Mawuenyega2, Bruce W Patterson3, Brian A Gordon4, Jennifer Jockel-Balsarotti2, Melissa Sullivan2, Matthew J Crisp2, Tom Kasten2, Kristopher M Kirmess3, Nicholas M Kanaan5, Kevin E Yarasheski3, Alaina Baker-Nigh3, Tammie L S Benzinger4, Timothy M Miller6, Celeste M Karch7, Randall J Bateman8.   

Abstract

We developed stable isotope labeling and mass spectrometry approaches to measure the kinetics of multiple isoforms and fragments of tau in the human central nervous system (CNS) and in human induced pluripotent stem cell (iPSC)-derived neurons. Newly synthesized tau is truncated and released from human neurons in 3 days. Although most tau proteins have similar turnover, 4R tau isoforms and phosphorylated forms of tau exhibit faster turnover rates, suggesting unique processing of these forms that may have independent biological activities. The half-life of tau in control human iPSC-derived neurons is 6.74 ± 0.45 days and in human CNS is 23 ± 6.4 days. In cognitively normal and Alzheimer's disease participants, the production rate of tau positively correlates with the amount of amyloid plaques, indicating a biological link between amyloid plaques and tau physiology.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; PET; SILK; amyloid; human; induced pluripotent stem cell; isoform; phosphorylation; positron emission tomography; production rate; stable isotope labeling kinetics; tau

Mesh:

Substances:

Year:  2018        PMID: 29566794      PMCID: PMC6137722          DOI: 10.1016/j.neuron.2018.02.015

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  80 in total

1.  N-terminal fragments of tau inhibit full-length tau polymerization in vitro.

Authors:  Peleg M Horowitz; Nichole LaPointe; Angela L Guillozet-Bongaarts; Robert W Berry; Lester I Binder
Journal:  Biochemistry       Date:  2006-10-24       Impact factor: 3.162

2.  Age and amyloid effects on human central nervous system amyloid-beta kinetics.

Authors:  Bruce W Patterson; Donald L Elbert; Kwasi G Mawuenyega; Tom Kasten; Vitaliy Ovod; Shengmei Ma; Chengjie Xiong; Robert Chott; Kevin Yarasheski; Wendy Sigurdson; Lily Zhang; Alison Goate; Tammie Benzinger; John C Morris; David Holtzman; Randall J Bateman
Journal:  Ann Neurol       Date:  2015-07-20       Impact factor: 10.422

3.  Propagation of tau pathology in a model of early Alzheimer's disease.

Authors:  Alix de Calignon; Manuela Polydoro; Marc Suárez-Calvet; Christopher William; David H Adamowicz; Kathy J Kopeikina; Rose Pitstick; Naruhiko Sahara; Karen H Ashe; George A Carlson; Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2012-02-23       Impact factor: 17.173

4.  Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture.

Authors:  Hans Zempel; Frank J A Dennissen; Yatender Kumar; Julia Luedtke; Jacek Biernat; Eva-Maria Mandelkow; Eckhard Mandelkow
Journal:  J Biol Chem       Date:  2017-05-23       Impact factor: 5.157

5.  Antisense reduction of tau in adult mice protects against seizures.

Authors:  Sarah L DeVos; Dustin K Goncharoff; Guo Chen; Carey S Kebodeaux; Kaoru Yamada; Floy R Stewart; Dorothy R Schuler; Susan E Maloney; David F Wozniak; Frank Rigo; C Frank Bennett; John R Cirrito; David M Holtzman; Timothy M Miller
Journal:  J Neurosci       Date:  2013-07-31       Impact factor: 6.167

6.  Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.

Authors:  Angela L Guillozet-Bongaarts; Francisco Garcia-Sierra; Matthew R Reynolds; Peleg M Horowitz; Yifan Fu; Tianyi Wang; Michael E Cahill; Eileen H Bigio; Robert W Berry; Lester I Binder
Journal:  Neurobiol Aging       Date:  2004-12-16       Impact factor: 4.673

7.  Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity.

Authors:  Nicolas R Barthélemy; François Fenaille; Christophe Hirtz; Nicolas Sergeant; Susanna Schraen-Maschke; Jérôme Vialaret; Luc Buée; Audrey Gabelle; Christophe Junot; Sylvain Lehmann; François Becher
Journal:  J Proteome Res       Date:  2016-01-19       Impact factor: 4.466

Review 8.  Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Authors:  Harald Hampel; Kaj Blennow; Leslie M Shaw; Yvonne C Hoessler; Henrik Zetterberg; John Q Trojanowski
Journal:  Exp Gerontol       Date:  2009-10-22       Impact factor: 4.032

9.  Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies.

Authors:  Celeste M Karch; Amanda T Jeng; Alison M Goate
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

Review 10.  Tau in physiology and pathology.

Authors:  Yipeng Wang; Eckhard Mandelkow
Journal:  Nat Rev Neurosci       Date:  2015-12-03       Impact factor: 34.870

View more
  137 in total

1.  Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.

Authors:  Sebastian Palmqvist; Pontus Tideman; Nicholas Cullen; Henrik Zetterberg; Kaj Blennow; Jeffery L Dage; Erik Stomrud; Shorena Janelidze; Niklas Mattsson-Carlgren; Oskar Hansson
Journal:  Nat Med       Date:  2021-05-24       Impact factor: 53.440

Review 2.  SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases.

Authors:  Ross W Paterson; Audrey Gabelle; Brendan P Lucey; Nicolas R Barthélemy; Claire A Leckey; Christophe Hirtz; Sylvain Lehmann; Chihiro Sato; Bruce W Patterson; Tim West; Kevin Yarasheski; Jonathan D Rohrer; Norelle C Wildburger; Jonathan M Schott; Celeste M Karch; Selina Wray; Timothy M Miller; Donald L Elbert; Henrik Zetterberg; Nick C Fox; Randall J Bateman
Journal:  Nat Rev Neurol       Date:  2019-06-20       Impact factor: 42.937

3.  Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry.

Authors:  Eric Vallabh Minikel; Eric Kuhn; Alexandra R Cocco; Sonia M Vallabh; Christina R Hartigan; Andrew G Reidenbach; Jiri G Safar; Gregory J Raymond; Michael D McCarthy; Rhonda O'Keefe; Franc Llorens; Inga Zerr; Sabina Capellari; Piero Parchi; Stuart L Schreiber; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2019-09-26       Impact factor: 5.911

Review 4.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

5.  MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.

Authors:  Jennifer L Whitwell; Nirubol Tosakulwong; Christopher G Schwarz; Hugo Botha; Matthew L Senjem; Anthony J Spychalla; J Eric Ahlskog; David S Knopman; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs
Journal:  Mov Disord       Date:  2018-11-23       Impact factor: 10.338

Review 6.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Authors:  Justin M Long; David M Holtzman
Journal:  Cell       Date:  2019-09-26       Impact factor: 41.582

7.  Biomarkers of Alzheimer Disease.

Authors:  Melissa M Budelier; Randall J Bateman
Journal:  J Appl Lab Med       Date:  2020-01-01

Review 8.  It's complicated: The relationship between sleep and Alzheimer's disease in humans.

Authors:  Brendan P Lucey
Journal:  Neurobiol Dis       Date:  2020-07-29       Impact factor: 5.996

Review 9.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

10.  Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo.

Authors:  Tomas Ondrejcak; Igor Klyubin; Grant T Corbett; Graham Fraser; Wei Hong; Alexandra J Mably; Matthew Gardener; Jayne Hammersley; Michael S Perkinton; Andrew Billinton; Dominic M Walsh; Michael J Rowan
Journal:  J Neurosci       Date:  2018-10-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.